Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy

Hematol Oncol. 2024 Jan;42(1):e3243. doi: 10.1002/hon.3243. Epub 2023 Dec 16.

Authors

Hazim S Ababneh¹, Matthew J Frigault², Andrea K Ng³, Chirayu G Patel¹

Affiliations

¹ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

PMID: 38103211
DOI: 10.1002/hon.3243

No abstract available

Publication types

Letter

MeSH terms

Cell- and Tissue-Based Therapy
Central Nervous System
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma* / etiology
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen